Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01316692 | Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV… | Phase 2 | terminated | Mar 16, 2011 | Vanderbilt-Ingram Cancer Center | low accrual | Enrollment / accrual |
| NCT00991991 | Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III… | — | terminated | Oct 8, 2009 | Case Comprehensive Cancer Center | Not enough tissue for analysis | Other (stated, no rule matched) |
| NCT02061007 | Biomarker Correlates of Hypoxia in Metastatic Melanoma | Phase 2 | withdrawn | Feb 12, 2014 | H. Lee Moffitt Cancer Center and Research Institute | no accrual | Enrollment / accrual |
| NCT00897312 | Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C,… | — | terminated | May 12, 2009 | Vanderbilt-Ingram Cancer Center | slow accrual | Enrollment / accrual |
| NCT00716495 | Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the… | Phase 1 / Phase 2 | terminated | Jul 16, 2008 | AGIRx Ltd. | problems in funding | Funding |
| NCT02065466 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | Phase 1 / Phase 2 | withdrawn | Feb 19, 2014 | University of Arizona | lack of accrual | Enrollment / accrual |
| NCT00613509 | Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma | Phase 2 | terminated | Feb 13, 2008 | Sanofi Pasteur, a Sanofi Company | No safety concerns, the study was terminated due to slow enrollment. All enrolled patients were… | Safety / toxicity |
| NCT01700114 | Post-Approval Study of MelaFind | — | terminated | Oct 4, 2012 | MELA Sciences, Inc. | FDA withdrew requirement to complete study | Other (stated, no rule matched) |
| NCT01730157 | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver… | Early Phase 1 | terminated | Nov 21, 2012 | Case Comprehensive Cancer Center | Research Cancelled | Other (stated, no rule matched) |
| NCT01200342 | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | Phase 2 | terminated | Sep 13, 2010 | M.D. Anderson Cancer Center | Pharmaceutical company no longer manufacturing investigational product. | Drug supply |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in… | Phase 1 / Phase 2 | withdrawn | May 22, 2015 | Rabih Said | PI departure, operational issues | Other (stated, no rule matched) |
| NCT00673361 | Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma | Phase 2 | terminated | May 7, 2008 | Duke University | not stated | Not stated |
| NCT00568451 | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | Phase 2 | terminated | Dec 6, 2007 | Mayo Clinic | Slow accrual. | Enrollment / accrual |
| NCT02357732 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | Phase 1 | withdrawn | Feb 6, 2015 | University of Pittsburgh | PI decided not to proceed | Other (stated, no rule matched) |
| NCT00003715 | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | Phase 2 | terminated | Apr 23, 2004 | AVAX Technologies | Terminated: recruiting or enrolling participants has halted prematurely and will not resume;… | Enrollment / accrual |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in… | Phase 2 | terminated | Oct 18, 2012 | Bristol-Myers Squibb | Discontinued early due to enrollment challenges and changes in treatment standards | Enrollment / accrual |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | Phase 1 / Phase 2 | terminated | Nov 8, 2010 | National Institutes of Health Clinical Center (CC) | Unexpected toxicities, likely due to TIL/IL-12 \& low % of durable responses. | Safety / toxicity |
| NCT01474551 | Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally… | Phase 2 | terminated | Nov 18, 2011 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00006126 | Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell… | Phase 1 | withdrawn | Mar 8, 2004 | Northwestern University | Unable to accrue subjects. | Enrollment / accrual |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | Phase 2 | terminated | Feb 7, 2008 | National Cancer Institute (NCI) | The study was terminated due to low accrual. | Enrollment / accrual |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | Phase 2 | terminated | Feb 11, 2008 | National Cancer Institute (NCI) | The study was terminated due to low accrual. | Enrollment / accrual |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating… | Phase 2 | terminated | Jun 25, 2008 | National Institutes of Health Clinical Center (CC) | Terminated due to withdrawal of support from our collaborator. | Other (stated, no rule matched) |
| NCT00706992 | Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | Phase 2 | terminated | Jun 30, 2008 | National Cancer Institute (NCI) | \<11 subjects were enrolled to each Arm | Enrollment / accrual |
| NCT01160445 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab… | Phase 2 | terminated | Jul 12, 2010 | National Cancer Institute (NCI) | The study was terminated because we were not able to obtain the study drug. | Other (stated, no rule matched) |
| NCT01273181 | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered… | Phase 1 / Phase 2 | terminated | Jan 10, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | Phase 2 | terminated | Dec 20, 2011 | National Cancer Institute (NCI) | Due to slow accrual, the investigator decided to close the study. | Investigator |
| NCT00093678 | Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer | N/A | withdrawn | Oct 8, 2004 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT01783431 | Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells | Phase 1 | terminated | Feb 4, 2013 | Medical University of South Carolina | The study was terminated early due to low accrual. | Enrollment / accrual |
| NCT01045915 | Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or…(AMEP) | Phase 1 | terminated | Jan 11, 2010 | Valerio Therapeutics | The study has been halted due to the low enrolment rate. | Enrollment / accrual |
| NCT01764009 | Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients…(AIMM) | Phase 1 / Phase 2 | withdrawn | Jan 9, 2013 | Valerio Therapeutics | Study stopped due to low enrolment rate. | Enrollment / accrual |
| NCT02507076 | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma… | N/A | withdrawn | Jul 23, 2015 | Albert Einstein College of Medicine | no enrollment | Enrollment / accrual |
| NCT00996827 | Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma | — | terminated | Oct 16, 2009 | New Mexico Cancer Research Alliance | Sufficient samples collected when 73% of target enrollment was reached. | Enrollment / accrual |
| NCT00776945 | Feasibility and Functionality of fPAM Imaging in Melanoma(fPAM) | — | terminated | Oct 22, 2008 | Washington University School of Medicine | no funding | Funding |
| NCT01085396 | Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact… | — | terminated | Mar 11, 2010 | University of Pittsburgh | Ran out of funding | Funding |
| NCT01216436 | Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell… | Phase 1 | terminated | Oct 7, 2010 | Duke University | The PI retired | Other (stated, no rule matched) |
| NCT02442466 | Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma | Early Phase 1 | terminated | May 13, 2015 | MelCure SA | Difficulties to recruit on time the required patient population. | Enrollment / accrual |
| NCT00482105 | Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin…(DermTech) | N/A | terminated | Jun 4, 2007 | University of California, Davis | Withdrawn per sponsor and Investigator | Investigator |
| NCT01851408 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or… | Phase 2 | withdrawn | May 10, 2013 | National Cancer Institute (NCI) | No progression of Phase 1 trial to Phase 2. | Other (stated, no rule matched) |
| NCT00661336 | A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus… | Phase 1 | withdrawn | Apr 18, 2008 | Duke University | The study was withdrawn due to lack of patients. | Other (stated, no rule matched) |
| NCT00072189 | A Phase II Study of UCN-01 in Metastatic Melanoma | Phase 2 | terminated | Nov 6, 2003 | National Cancer Institute (NCI) | Early termination for discouraging results | Other (stated, no rule matched) |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | Phase 1 / Phase 2 | terminated | Jun 9, 2011 | National Cancer Institute (NCI) | Closed this protocol due to autoimmune toxicity. | Safety / toxicity |
| NCT01400451 | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene… | Phase 1 | terminated | Jul 22, 2011 | Bristol-Myers Squibb | More than 2 of 6 patients treated experienced dose limiting toxicities. | Safety / toxicity |
| NCT01593579 | Autonomic Phenotype Before and After Akt Inhibition | — | withdrawn | May 8, 2012 | Vanderbilt University | Planned parent study never enrolled | Enrollment / accrual |
| NCT01835184 | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma… | Phase 1 | terminated | Apr 18, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01841463 | Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With… | Phase 1 | suspended | Apr 26, 2013 | Piramal Enterprises Limited | Sponsor decision not related to patient safety | Safety / toxicity |
| NCT01531244 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2012 | Washington University School of Medicine | not stated | Not stated |
| NCT01123304 | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma | Phase 1 | terminated | May 14, 2010 | Morphotek | This study has been terminated due to lack of availability of investigational product. | Other (stated, no rule matched) |
| NCT01212276 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | Phase 1 | terminated | Sep 30, 2010 | Morphotek | Sponsor terminated protocol | Other (stated, no rule matched) |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | Phase 1 | terminated | Mar 26, 2004 | Yale University | not stated | Not stated |
| NCT01519427 | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV… | Phase 2 | terminated | Jan 27, 2012 | National Cancer Institute (NCI) | Study terminated due to slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 30, 2016source: clinicaltrials